Broderick Brian C Has $872,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Broderick Brian C decreased its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 6,795 shares of the company’s stock after selling 885 shares during the period. Broderick Brian C’s holdings in Novo Nordisk A/S were worth $872,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in NVO. Capital International Investors increased its position in shares of Novo Nordisk A/S by 22.3% during the 4th quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock worth $736,121,000 after purchasing an additional 1,297,536 shares in the last quarter. International Assets Investment Management LLC increased its position in Novo Nordisk A/S by 10,359.2% in the 4th quarter. International Assets Investment Management LLC now owns 819,688 shares of the company’s stock valued at $84,797,000 after acquiring an additional 811,851 shares in the last quarter. American Century Companies Inc. increased its position in Novo Nordisk A/S by 184.8% in the 3rd quarter. American Century Companies Inc. now owns 1,098,332 shares of the company’s stock valued at $99,882,000 after acquiring an additional 712,745 shares in the last quarter. Norden Group LLC increased its position in Novo Nordisk A/S by 2,456.0% in the 1st quarter. Norden Group LLC now owns 658,856 shares of the company’s stock valued at $84,597,000 after acquiring an additional 633,079 shares in the last quarter. Finally, Sapient Capital LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at about $65,340,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.1 %

Novo Nordisk A/S stock traded down $2.95 during midday trading on Thursday, hitting $139.79. 3,836,482 shares of the stock were exchanged, compared to its average volume of 4,448,043. The company has a fifty day simple moving average of $137.68 and a two-hundred day simple moving average of $125.97. Novo Nordisk A/S has a 52 week low of $75.96 and a 52 week high of $148.15. The stock has a market capitalization of $627.31 billion, a PE ratio of 48.20, a P/E/G ratio of 1.41 and a beta of 0.41. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The business had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Equities research analysts anticipate that Novo Nordisk A/S will post 3.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, July 1st. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Finally, Argus raised their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.